HumanCD4+T-cells recognize antigenic peptides in the context of humanleukocyte antigen (HLA) class II molecules and produce various lymphokines to proliferate and activate other cells. It was once considered that the T-cell response is an all or nothing type event, but recent studies have clearly indicated that T-cells show manydifferent types of activation in recognition of altered ligands for T-cell receptors (TCR). In this review, wesummarizeour recent findings on the human CD4+T-cell response to altered peptide ligands (APL); peptides carrying single residue substitutions in antigenic peptides. Weobserved the following: 1) TCRantagonism for T-cell clones reactive to non-self or autoantigenic peptides, 2) partial activation (agonism) without cell proliferation, including production of lymphokinesand increases in cell size, and in expression levels of several cell surface proteins or survival time in the absence of antigenic stimulus, 3) augmentation in cell proliferation and production of interferon-y (IFN-y) and granulocyte monocyte colony stimulating factor (GM-CSF), 4) augmentation of interleukin (IL)-12 production by antigen presenting cell (APC) and the subsequent augmented production of IFN-y by T-cells. This information provides basic knowledge regarding the characteristics of T-cell recognition of antigens and the subsequent activation, and a novel method for modification of humanT-cell responses by altered peptide ligands (APLs), as a possible candidate for antigen-specific immunopotentiating or immunosuppressive therapy against autoimmune diseases, allergies, infectious diseases and malignant tumors. (Internal Medicine 37: 804-817, 1998) 
Introduction
The human leukocyte antigen class-II (HLA-II) molecule is a highly polymorphic heterodimeric membraneprotein consisting of a and p chains and is expressed on B cells, antigen presenting cells (APC) and activated T-cells. As shown in Fig.  1A , the HLA-II molecule has a peptide binding groove on top of the molecule and binds antigenic peptides processed by APC to present them to CD4+T-cells [see review 1] . The structural requirements for HLA-II binding peptides were determined based on many combinations ofHLA-II molecules and peptides (2) (3) (4) (5) (6) . Three to five amino acid residues were separated by one to two intervening residue(s) and acted as anchor residue(s) for A. Presentation of peptides derived from extracellular or membranenon-self or selfproteins to CD4+T cells by HLAclass II molecules expressed on an antigen presenting cell, ocl, oc2, (31 and (32 indicate the extracellular domains of a and p chains of HLAclass II molecules. Va, V(3, Ca and C(3 indicate variable and constant-regions ofT-cell receptor a and (3 chains, respectively. B. The structure ofa peptide-binding groove of the HLAclass II molecule. The top of ocl and (31 domains is a groove-like structure consisting ofa (3-sheet floor and two side walls madeof two anti-parallel a-helices. There are five pocket-like structures indicated by circles in the groove and the side-chains of PI (the most N-terminal 1st DRanchor position), P4, P6, P7 and P9 anchor residues of the binding-peptide are accommodated in each pocket as shown in this figure. Black colored residues are polymorphic in HLA-DRmolecules.
Internal Medicine Vol. 37, No. 10 (October 1998) in structures of peptides bound to HLA-II molecules. In other words, polymorphism of HLA-II molecules determines individual differences in T-cell responses to a given antigenic peptide. CD4+T-cells usually recognize non-self peptides in the context of selfHLA-DRmolecules. Recognition and responses of T-cells were once considered to be an on/off phenomenon, but recent findings obtained using analogue peptides carrying single residue substitutions in antigenic peptides presented by one major histocompatibility complex (MHC) class II molecule (1 1-23) or one specific peptide presented by different MHC class II molecules showing a limited polymorphism (13, 24, 25) , revealed that altered TCRligands induce altered T-cel] responses. As shown in Fig. 2 , altered peptide ligands (APLs) carrying amino acid substitutions in an antigenic peptide, induce T cell nonresponsiveness, through TCRantagonism ( 14, 16, 17, 24) or anergy induction as a consequence of partial agonism or incomplete activation (15, 18) , and sometimes induce dissociation between proliferative response, cytotoxicity and cytokine production (12, 13) . These altered T-cell responses to various altered TCRligands were evidenced in mice (12, 13, 15, 18, 24) andinhumans (ll, 14, 16, 17, 19- Figure 2 . Altered responses of a CD4+T-cell clone induced by recognition of APLscarrying residue substitutions in an antigenic peptide. CD4+T-cells usually recognize non-self antigenic peptides in the context of MHCclass II molecules to produce lymphokines and proliferate. These TCRligands are designated as full agonists. APLshaving marked changes in conformation do not stimulate activation in T-cells because of loss of the capacity to bind to MHCmolecules or to be recognized by TCRand these APLs are irrelevant for recognition by T-cells.
In the presence of excess amounts of some APLs plus MHCclass II molecules, T-cell activation induced by a minimal amount of wild type peptide plus MHCmolecules is inhibited. These APLs are designated as TCR antagonists and they can make contact with TCRswith a lower affinity and/or a larger off-rate than do wild type TCRligands. However, they do not stimulate T-cell proliferation so that these APLs antagonize interactions between TCRs and their full agonistic ligands. Some TCRantagonistic APLspartially activate T-cells without stimulating cell proliferation and these APLs are designated as partial agonists. Note that partial agonists are distinct from weak full agonists which stimulate the small proliferative response of T-cells, at high doses. Details of partial activations (agonism) of T-cells by APLs are described in the text.
Modification of HumanT-Cell Responses by APLs 25).
In mouse T-cell clones, TCRantagonists or partially agonistic APLs induce partial phosphorylation of CD3£chains leading to the absence of phosphorylation and activation of ZAP70 (26, 27) . Studies of calcium signaling activity in mouse T-cells stimulated with APLs indicated that the Ca2+ response induced by antagonistic APLswas smaller in amplitude and shorter in duration than that induced by fully agonistic ligands (28) (29) (30) . Studies on a mouse T-cell clone also showed that the APL-stimulated Ca2+ response is initiated and sustained at lower levels than that stimulated by a strong agonistic signal, but it resembles that stimulated by a weaker agonistic stimulus (28, 30) . derived from a non-self antigenic peptide presented by Asianspecific DR4(DRB 1 *0406), which is associated with susceptibility to the insulin autoimmune syndrome (Hirata' s disease) unique to Asian populations (32). Weinvestigated the frequencies and characteristics of TCR agonism and TCRantagonism, with or without partial activation. The CD4+ human T-cell clone YN5-32 recognizes a streptococcal M12p54-68 pepide in the context of HLA-DR4 (DRA+DRB 1*0406) and produces a large amount of interferon-y(IFN-y) and a small amount ofIL-4. Weinvestigated the responses of YN5-32 to 154 independent analogue peptides carrying single residue substitutions at residues 57 (P l )-65 (P9) of the peptide where P1 (position 1) means the putative most Nterminal DRanchor residue (20) . As shown in Fig. 3 , the residues Leu-57 (PI), Ala-60 (P4) and Asn-62 (P6) were the most likely to be DR-anchor residues, and 30% (17/57) of analogue peptides substituted at these residues exhibited full agonismto stimulate various magnitudesof proliferative re- YN5-32 responds better to M12p54-68 presented by allogeneic DRB1*0403 with a single Tyr-substitution at DRp37-Ser of the DRB1 *0406 molecule. Because single amino acid polymorphism at residue 37 of the HLA-DRpchain (DRp37) between DRB1*0406 and 0403 markedly influences the susceptibility to the insulin autoimmune syndrome (32), we investigated the effects of DRp37polymorphism regarding recognition of non-self peptides by . One hundred and fiftyfour analogue peptides described above were tested for fully agonistic and TCRantagonistic activities. Forty-six peptides showed full agonism, thirty-four analogues exhibited TCR antagonism and forty-five analogues exhibited neither full agonism nor TCRantagonism, irrespective of the presenting molecules DRB1*0406 or DRB1*0403. On the other hand, twenty-nine analogue peptides substituted at each of residues 57(P1)-63(P7) of M12p54-68 were recognized differently by YN5-32, depending on the presenting HLA-DRmolecules. These observations indicate that 1) single amino acid polymorphism (Ser-Tyr) at the DRp37 residue induced conformational changes ofpeptides, which can be distinguished by TCRof the T-cell clone in some but not all peptides; and 2) these conformational changes were observed even in APLs carrying single residue substitutions at residues far from a putative DR(337 contact site. These findings provide further evidence for altered human T-cell responses induced by minor modifications of TCRligands.
Immuno-SuppressivePeptides Acting on a T-Cell Clone Autoreactive to Acetylcholine Receptor ( The distribution of the age at onset of Japanese MGpatients shows bimodal peaks: the first and the highest peak is seen before the age of3 years and the second lowerpeak occurs in the third decade of life (36). In contrast, in Caucasians, the age at onset of MGgenerally shows a single peak in adulthood (37), in which susceptibility to MGis associated with HLA-DR3 and HLA-B8(38, 39). In the Japanese patients in whomthe disease developed before the age of3 years old, the frequencies ofHLA class II haplotypes commonin the Asian populations, HLA-DR9(DRBl *0901)-DQ9(DQAl *0301-DQBl *0303), DR13(DRB1 *13O2)-DQ6(DQA1 *0102-DQBl *0604) and their double-heterozygotes were significantly increased (40, 41).
Clinical manifestations of myasthenia are also different between infant-onset MGand adult-onset MG. The former has a relatively benign prognosis and affects mainly ocular muscles without causing severe and generalized muscle weakness. The AChRof mature muscle consists of five subunits in the stoichiometry of two a, one each p, 8 and 8 subunits (42) . The AChRocsubunit exists in two isoforms, with or without a peptide encoded for by exon P3A which can be alternatively spliced (43, 44) . Their functional difference is unknown. The binding sites of the anti-AChR auto-antibodies locate at an extracellular region of the a subunit, designated as the main immunogenic region (45). The acetylcholine binding sites of AChR consist of a-y(e) and oc-8 complexes, and epitopes recognized by CD4+ocp autoreactive T-cells have been identified in AChR a, p, yand 5 subunits in MG(46-50). To elucidate the mechanismsinvolved in susceptibility to infant-onset MGassociated with HLAclass II alleles, we established and analyzed an AChRa-autoreactive CD4+ ap Tcell clone from a Japanese patient with infant-onset MGand we analyzed the effects of analogue peptides derived from an autoantigenic peptide, on the immune responses of the autoreactive T-cell clone (51). An AChRap71-91 peptide-specific autoreactive CD4+a(3 T-cell clone was established by stimulating peripheral blood mononuclear cells from a patient heterozygous for two disease-susceptible HLA-DR9-DQ9and DR12-DQ6 haplotypes with a mixture of overlapping peptides covering AChRocsubunit. The T cell clone recognized the AChRapeptide in the context of the HLA-DQ6 molecule and produced a large amountof IFN-y and a trace amountof interleukin (IL)-4 showing a Th l -like phenotype. The majority (p75-83) of the core epitope of the autoantigenic peptide (p75-87) is encoded for by exon P3A of the AChRa gene which can be alternatively spliced. In Caucasian MG,T-cells autoreactive to this AChRaepitope are rarely noted (50). The T cell clone responds to the recombinant AChRaprotein with a P3A exon product, but not without a P3A exon product. Because analogues of the antigenic peptides substituted at TCR-recognition residues are good candidates for immunosuppressive peptides with a TCRantagonistic property, we applied this knowledge to determine inhibitory APLs which specifically act on AChRaautoreactive T-cells. For this, we investigated the responses of T-cell clone to 1 14 analogue peptides carrying single residue substitutions in the core AChRapeptide. The majority of APLssubstituted at either residue Phe-77, Leu-80 or Asn-82 stimulated proliferation of the T-cell clone. Conversely, the majority of analogue peptides substituted at either Gin-81 or Glu-83 did not stimulate proliferative responses, which suggested that these two residues may be TCR contact sites. As shown in Fig. 4 molecules, it would be recognized by T-cells and could serve as a target for antigen-specific tumor immunity. Indeed, human Tcells that recognize mutated Ras protein and/or peptide have been noted in healthy donors (55-58) and in cancer patients (59-63). These T-cells can play a role in host-cancer interactions (60), and adoptive transfer of these T-cells or immunization with mutated p21-Ras derived peptides may be one strategy for the design of cancer immunotherapy. In animal models, immunization with a mutated p2 1-Ras protein elicited protective immunity against a challenge with tumor cells carrying the corresponding mutation, and therapeutic benefit was achieved in mice bearing tumors expressing the same mutated p21-Ras protein (64). (3, 7, 10, 67, 68) . As shown in Fig. 5 , the proliferative response and production of GM-CSF (73), and those of Derfl were identified in our laboratory (78). Wegenerated humanT-cell lines and clones specific to Der /I and investigated the effects of analogue peptides on alterations of T-cell responses (22). Using a panel of overlapping synthetic peptides that cover the entire Derf l molecule, we demonstrated that polyclonal Der/I-specific T-cell lines prepared from the peripheral blood of five atopic patients that cover most of the commonHLAhaplotypes in the Japanese population, can respond to 13 different epitopes of the molecule. Each donor showed a different pattern ofreactivity with the synthetic peptides, with some overlaps. One of these Z)er/I-specific Tcell clones DTI3.2, established from a patient with bronchial asthma, recognized an antigenic peptide Derfl pi8-3 1 in the context of HLA-DQ6(DQAl *0102-DQB 1*0602) molecules and secreted both interleukin-4 and interferon-y.
As shown in Fig. 6 , analysis of changes in DTI3.2responses to Derfl pi8-3 1-derived analogue peptides revealed that the substitution of 21Arg to Lys resulted in a significant increase in interferon-y production, with no remarkable changes either in proliferative response or interleukin-4 production. Tyrosine phosphorylation induced by the analogue peptide was higher in magnitude than that induced by the wild-type peptide, without qualitative differences. Interestingly, the selective enhancement of IFN-yby the analogue peptide was accompanied by increased production ofIL-1 2, which was suppressed by anti IL-12 antibody down to the level of IFN-y production induced by the wild-type peptide. Because IFN-y stimulates production by APC, it would seem that APL primarily augmented IFN-yproduction by T-cells to enhance IL-12 production by APC. But this is not the case, because even in the presence of sufficient amounts of anti-IFN-y and anti-IFN-y receptor antibodies for neutralization of biological activity of IFN-y, the augmented production ofIL-1 2 remained unchanged. These results collectively indicate that some APLs induce certain altered signaling within APC, which may eventually lead to the qualitative changes in T-cell responses. Our observations suggest that the modeof interaction betweenTCRand MHC+peptide complex may determine Th l -predisposing condition by controlling IL-12 production by APC. Furthermore this kind ofTh 1 -response inducing APLsmay provide a peptide therapy for diseases caused by Th2 responses such as allergy.
A Self-Homologue of a Non-Self Antigenic Peptide Exhibits Partial Agonism to Prolong Clonal Survival of Effector T-Cells in vitro Weare also investigating the biological significance of human T-cell responses to APLs. A self-homologue of a nonself antigenic peptide may contribute to maintain the survival of T-cells specific to non-self antigens. It was reported that recognition of APLs supports survival and differentiation of thymocytes in the thymus, an event knownas positive selection (79, 80) . In addition to one-residue substituted analogues of wild-type peptides, non-self-reactive T-cell clones can be fully or partially be activated by minimally homologous self-peptides Figure 6 . Scheme for augmented T-cell production ofIFN-yinduced by IL-12 produced from antigen presenting cells in response to an altered peptide ligand. A Derf I-specific T-cell clone DT13.2, established from a bronchial asthma patient, recognized an antigenic peptide Derfl pl8-31 in the context of HLA-DQ6 (DQAl*0102-DQBl*0602)molecules and secreted both interleukin-4 and interferon-y. Derfl pi8-31-derived analogue peptide, R21K having substitution of 21Arg to Lys, induced enhancement of interferon-y production by DT13.2, with no remarkable changes either in proliferative response or interleukin-4 production. This phenomenonwas accompanied by the increased production of IL-12 by APC, and was suppressed by anti-IL-12 antibody down to the level of IFNy production induced by the wild-type peptide. Augmented production of IL-12 by APCstimulated with R21Kwas still observed in the presence of anti-IFN-yand anti-IFN-yreceptor antibodies. These results collectively indicate that someanalogue peptides induce a certain altered signaling within APC, which may eventually lead to the qualitative changes in T-cell responses. (8 1, 82) , or vice versa; i.e., self-reactive T-cells are activated by non-self-peptides known as "molecular mimicry in autoimmunity" (83, 84). However, the roles of peptide partial agonists in the survival of mature T-cells remain elusive. If this takes place, it may provide supportive evidence that selfhomologuesofnon-self antigenic peptides maintain survival of the antigen-specific T-cells to create immunological memory. Weasked whether non-self Bacillus Calmette-Guerin (BCG)-reactive human CD4+ T-cell clones can be partially activated by analogue or minimally homologous self-peptides to prolong survival in vitro.
T-cell clones and peptides used for the study We established three independent CD4+ ThO clones from The wild-type BCGap84-1 00 induced proliferation of the Tcell clones at peptide concentrations as low as 100 pMand in a dose-dependent manner. The self homologue, humanconnexin 26p33-49 (HCp33-49; IMILVVAAKEVWGDEQA) did not induce proliferation of all three T-cell clones, even at 10 jiM. However, D93Estanding for an analogue peptide carrying Glu(E)-substitution at the 93rd residue Asp(D) of BCGap84-100 peptide and D93Y peptides did induce proliferation of BC42.1 at 10 jiM, thereby indicating that they bind to DR14 molecules. D93Yinduces very weak proliferation ofBC33.5 at 10 \\M butnotat 3 jiM or 1 \xM.
Sustained viability and T-cell proliferation after stimulation with non-fully agonistic peptides Wethen asked whether the self homologueand analogue peptides described above would be capable of prolonging T-Modification of HumanT-Cell Responses by APLs cell survival in vitro at concentrations below the optimal concentration required for induction of proliferation or at 10 [iM for peptides that do not induce T-cell proliferation. To investigate the antigen-specific proliferative response of surviving T-cells, T-cells were co-incubated with irradiated autologous PBMCin the presence of various peptides that do not induce T-cell proliferation, followed by the addition of irradiated autologous PBMCpulsed with the wild-type peptide, one to nine days after the initial stimulation. After preincubation with 10 |iM HCp33-49, the proliferative responses of BC20.7 were significantly higher upon re-stimulation with the wildtype peptide. A similar observation was noted for BC33.5 preincubated with 1 jiM ofD93Y (p<0.01 on days 1, 3, 5, and 7) . In striking contrast, pre-incubation with 10 pM of the wildtype peptide, below the optimal concentration for the induction of proliferation, did not enhance proliferation of T-cells upon re-stimulation as compared with a mediumonly control. Preincubation with the other peptides showed no differences from those in the case of mediumalone. Moreover, trypan blue exclusion assay with the same combination of T-cells and peptides exhibited viable cell counts parallel to the results (p<0.05 at days 1, 3, 5, 7, and 9) . Flow cytometric analysis confirmed that survival of specific TCR Vp-bearing T-cells but not feeder cells was enhanced. Because day 5 after the stimulation with D93Y or HCp33-49 was optimal to observe effects on survival, the dose response to these peptides of T-cell survival was tested on day 5. As shown in Fig. 7A , B, and C the effects were dose dependent and clone specific. Thus, T-cell clones pretreated with higher concentrations of appropriate APLs, including self HCp33-49 peptide, exhibited a stronger proliferative response to the wild-type peptide, thereby indicating that survival of competent T-cells was prolonged in a manner dependent on the dose of APL.
Because partially agonistic TCR-ligands reported previously exhibited TCR antagonism, we investigated TCRantagonistic activity of T-cell survival-prolonging peptides, using so-called pre-pulse assay where APCs are prepulsed with lowdose wild-type peptide followed by incubation with T-cells in the presence of high-dose soluble APLs (20) . D93Y peptide antagonized the response to wild-type peptide of BC20.7 and BC33.5 clones, and HCp33-49 peptide did so in BC20.7 and BC42. 1 clones, indicating that these peptides are recognized by TCR, in combinations where prolonged T-cell reactivity is observed.
Certain peptide partial agonists can reportedly induce a state of T-cell anergy (15, 18, 81, 87) . However, in our human systems with an M12-reactive T-cell clone (20) and BCGareactive T-cell clones (87), BC20. Peptide concentration (juM) Figure 7 . Sustained T-cell proliferation after stimulation with non-fully agonistic peptides. All three T-cell clones BC20.7 (A), BC33.5 (B) and BC42.1 (C) were cultured either with medium (closed circle), protect cells from apoptosis (90). Wethen tested the expression of Bcl-2 and Bcl-x proteins after stimulation with survivalinducing APLs and control. The results indicate that: 1) enhancement of Bcl-xL expression through TCR-mediated signaling induced by certain partially agonistic APLs, is not always associated with proliferation; and 2) peptide-induced Tcell clonal survival is associated with upregulation of Bcl-xL expression. Avariety of stimuli trigger the apoptotic death ofTcells, which is further regulated by a set of genes that function as repressors. The bcl-2 protooncogene was the first identified memberof this gene family that was found to suppress the apoptotic mechanism (90). In human peripheral T-cells, Bcl-x protects cells from anti-CD3-mediated (91, 92), anti-Fas-induced and IL-2-withdrawal-induced apoptosis (93). Indeed, in our current study using humanmature T-cell clones, T-cell survival induced by certain partially agonistic APLs showed a close association with the upregulation of Bcl-xL, although the precise mechanism that leads to enhanced Bcl-xL expression without proliferation is not yet clear. Moreover,expression levels ofCD28, Fas/FasL, Bax or Bad did not change in cultures with T+irradiated PBMC+peptides that induce T-cell survival. Whenwe examined whether or not these survival-inducing APLs are capable of activating T-cells to produce IL-4, we found that 1) survival-inducing peptides, although devoid of proliferation-inducing activity do bind to DR14 and stimulate T-cells to produce lymphokines, which means that they are partial agonists; and 2) T-cell-peptide combinations that induce lymphokine production without proliferation do not necessarily prolong T-cell survival. None of the partially agonistic APLsthat induced lymphokine production without survivalinducing activity, enhanced the T-cell expression of Bcl-xL. Thus, as summarized in Table 1 , survival-inducing activity of APLsis associated with the capacity to induce upregulation of Bcl-xL, but not lymphokine production. Adoptive transfer experiments revealed that in a population of CD8+T-cells, memorycould persist for a long time in the absence of wild-type antigen (94). Furthermore, analysis of memory in the CD8+ T-cell compartment by utilizing T-cell receptor transgenic mice expressing a transgenic TCRspecific for H-Y antigen, showed that memory cells can be derived from activated T-cells and persist in the absence of wild-type antigen (H-Y) for at least 13 weeks, in female nu/nu recipient mice (95). Although it is not clear whether T-cells are stimulated by endogenous partial agonistic APLs in these systems, it is suggested that T-cell memory is maintained in the absence of wild-type ligands. It is also noteworthy that long-term T-cell survival is difficult to maintain, in MHC-deficient mice (96). Our current study suggests that possible involvement of TCR partial agonism induced by self-homologues of non-selfpeptides presented by self-MHC molecules in the prolongation of T-cell survival and in the maintenance of T-cell memory.
In conclusion, analyses of T-cell responses to APLshas provided pertinent information on the basic immunology of Tcell biology and also on the strategy for new methods for modification of antigen-specific responses of T-cells.
